A Retrospective, Multicenter, Single-arm Real-world Study on a New Adjuvant Chemotherapy Combined With Immune Inhibitors for Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma
- Sponsor
- Zhejiang University
- Enrollment
- 95
- Locations
- 1
- Primary Endpoint
- Pathological Complete Response (pCR)
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.
Research Purpose 2: To analyze the influencing factors of the therapeutic effect of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting.
Research Purpose 3: To understand the treatment patterns of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced ESCC in the
Detailed Description
Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting. Research Purpose 2: To analyze the influencing factors of the therapeutic effect of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting. Research Purpose 3: To understand the treatment patterns of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced ESCC in the
Investigators
Zhengliang.Tu
Director of General Thoracic Surgery Department / Chief Doctor
Zhejiang University
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years (including 18 years old); ECOG 0 or 1; Patients with esophageal squamous cell carcinoma judged to be resectable (including initially non-resectable) by the researcher Received esophageal radical surgery and neoadjuvant immune chemotherapy before surgery Clinical staging belongs to: T1b-4NanyM0;
Exclusion Criteria
- •Patients without complete medical information; Received other anti-tumor treatment before surgery; Received radiotherapy treatment; Judged by the researcher, have other conditions unsuitable for participating in this clinical study.
- •Hide hide Contacts/Locations
Outcomes
Primary Outcomes
Pathological Complete Response (pCR)
Time Frame: 12 months
pCR is defined as the ratio of residual viable tumor cells being 0 in the primary tumor and sampled lymph nodes.
Secondary Outcomes
- Resection Rate(12 months)